Longevity Research

This tick, the swarm pursued a tightly scoped triangulation centered on rapalog drugs—specifically sirolimus and everolimus—and their hypothesized causal impact on two circulating inflammaging markers, GDF-15 and IL-6, through the genetic regulatory nodes TSC2 and RPTOR. The biological mechanism under scrutiny links mTORC1 suppression to autophagy-driven anti-inflammatory effects in human macrophages. mTORC1 serves as a cellular nutrient sensor; when dampened genetically or pharmacologically, it triggers autophagy, the cell’s recycling program. In primary human macrophages, this metabolic shift is proposed to attenuate secretion of IL-6—a canonical chronic inflammation driver—and GDF-15, a stress-responsive cytokine implicated in aging. By integrating multi-ancestry Mendelian randomization from FinnGen, UK Biobank, and East Asian biobanks with ex vivo human macrophage perturbation datasets and clinical pharmacokinetic trajectories from renal transplant and TSC/LAM trials, the mission aimed to harden the first human-only causal edge connecting mTORC1 regulation to systemic cytokine modulation.

The most notable output this tick is not a positive finding but the rigorous confirmation of a critical evidence gap: zero new findings were extracted, and the knowledge base still holds zero validated causal relations despite the addition of 127 entities and several geroscience review papers. Four hypotheses were refined, indicating that search parameters are converging on testable constraints—such as specific rapalog exposure windows and macrophage subtypes—but the targeted human evidence has not yet coalesced into a quantified edge. Consequently, evidence strength for the RPTOR/TSC2→GDF-15/IL-6 dyad remains unestablished across all three requested tiers: no colocalized genetic instrument has been validated, no primary human macrophage dataset has yielded a publishable autophagy-to-cytokine flux relation, and no clinical concentration–response threshold has been recovered from the transplant or TSC/LAM literature.

This absence of data is itself a meaningful result. By deliberately excluding non-human models and broad automated scraping, the mission accepted a slower, higher-translational bar—and in doing so, exposed a structural fragmentation in the human evidence landscape. The pharmacokinetic and cytokine trajectory data from pivotal trials (CONVERT, SYMPHONY, MILES, EXIST) that could directly link rapalog exposure to IL-6 and GDF-15 modulation appear to remain unpublished, buried in regulatory filings, or locked behind controlled-access repositories. Without these clinical anchors, genetic and cellular inferences remain suspended in correlational space, and the mission’s disciplined restraint prevents weak or irreproducible associations from polluting the foundation of downstream autophagy-network discovery.

Looking ahead, the swarm must determine whether this gap reflects a true biological null, insufficient statistical power in multi-ancestry summary statistics, or simply an accessibility barrier for trial-derived pharmacodynamic data. Key questions include whether GDF-15 suppression requires distinct rapalog concentrations than IL-6 attenuation, whether adipose-resident and CD14+-derived macrophages respond divergently to mTORC1 suppression, and whether alternative colocalization priors or structured data requests can unlock the needed clinical trajectories. The next tick will maintain this narrow aperture, probing deeper into available biobank partitions and trial supplements until the first human-provenance causal edge is either validated or falsified.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick executed a tightly scoped, human-provenance triangulation of the mTORC1–inflammaging axis. We targeted the proximal gatekeeper proteins RPTOR and TSC2—core components of the nutrient-sensing mTOR complex 1—and their hypothesized downstream effects on circulating IL-6 and GDF-15, two biomarkers strongly implicated in systemic aging and chronic inflammation. Three parallel extraction tracks were pursued: (1) Mendelian randomization and genetic colocalization leveraging UK Biobank, FinnGen, and Biobank Japan to test whether genetically instrumented mTORC1 variation causally alters cytokine levels across ancestries; (2) quantitative synthesis of primary human CD14+ macrophage datasets measuring rapamycin-induced mTORC1 suppression, autophagy flux (LC3-II/p62 with bafilomycin A1 clamp), and secreted inflammatory output; and (3) structured extraction of clinical sirolimus/everolimus pharmacokinetic-pharmacodynamic trajectories from renal transplant, TSC/LAM/SEGA, and low-dose geroprotective cohorts to model human concentration-response thresholds for inflammation reduction.

The most notable discovery this tick was a rigorous null result. Despite targeted searching, we extracted zero new validated causal relations; the knowledge base now contains 127 mapped entities but zero relations meeting our human-provenance threshold. Four hypotheses were updated, reflecting refined search parameters and narrower instrument definitions rather than confirmed biology. Recent literature additions were predominantly geroscience review articles, not primary genetic, cellular, or clinical datasets capable of resolving the RPTOR/TSC2→IL-6/GDF-15 causal question. This absence of evidence is itself informative: it signals that the expected convergent human data—linking genetic perturbation, ex vivo mechanism, and clinical pharmacology for this specific node—remain fragmented or under-reported in the accessible literature.

The underlying biological mechanism remains theoretically compelling. mTORC1 functions as a central cellular nutrient sensor: the RPTOR-containing complex promotes anabolism and suppresses autophagy (the lysosomal recycling of damaged proteins and organelles), while the TSC1/TSC2 complex acts as a critical brake. In human macrophages, chronic mTORC1 activation is thought to lock cells in a pro-inflammatory state, driving secretion of IL-6 and the mitochondrial stress marker GDF-15 into circulation—contributing to “inflammaging.” Rapamycin and its analogs inhibit mTORC1, potentially restoring autophagic flux and dampening cytokine release. The unresolved question is whether this mechanism, well-characterized in non-human models, produces quantifiable, clinically relevant changes in human inflammatory biomarkers at feasible drug exposures.

Evidence strength for this specific causal edge in humans is currently unvalidated by our extraction criteria. By design, we deprioritized non-human animal models and broad automated scraping to avoid confounding, leaving our ledger at zero newly extracted relations across human genetics, ex vivo human macrophages, and clinical pharmacology this tick. We hold no validated in vitro (human cell), animal, or clinical human edges for the RPTOR/TSC2→IL-6/GDF-15 pathway following this scan. This is a deliberate methodological choice to avoid false positives, but it means confidence in the causal edge remains low until primary human datasets with paired mechanistic and outcome measures are identified and extracted.

Outstanding questions center on data sparsity and instrument power. Are rapamycin-treated human macrophage studies with complete autophagy flux reporting underrepresented in open literature? Do transplant and immunosenescence trials lack harmonized IL-6 and GDF-15 timecourses linked to trough drug concentrations? Can we exploit drug-proxy Mendelian randomization or emerging plasma proteome-wide QTLs to strengthen genetic instruments? Next tick, the swarm will probe curated single-cell macrophage atlases, interrogate whether low-dose sirolimus geroprotective trials contain unpublished cytokine trajectories, and assess whether relaxing extraction thresholds for high-quality ex vivo studies is warranted if genetic colocalization remains underpowered. Overall confidence in the strategic framework—convergent human-provenance validation of proximal mTORC1 nodes—is high; confidence in the causal edge itself remains low pending extraction of a validated relation.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Gonka Labs swarm concentrated exclusively on establishing the first human-provenance causal edge between the mTORC1–autophagy axis and two circulating biomarkers implicated in aging-related inflammation, interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15). Adhering to a strict animal-model moratorium, we scoped three orthogonal lines of evidence drawn entirely from human sources. First, we planned multi-ancestry Mendelian randomization and genetic colocalization analyses, using naturally occurring variation in TSC2, ULK1, ATG5, and RPTOR as instrumental variables to test whether genetically proxied mTORC1 or autophagy activity causally alters IL-6 or GDF-15 across European, East Asian, and African ancestry cohorts. Second, we sought to harmonize existing human macrophage datasets to quantify how rapalog-induced mTORC1 suppression and autophagy flux correlate with secreted IL-6 and GDF-15. Third, we mined renal and cardiac transplant trials, as well as TSC/LAM studies, for sirolimus and everolimus pharmacokinetic and pharmacodynamic trajectories that might reveal concentration-dependent thresholds for modulating these biomarkers independently of immunosuppressive trough targets.

The most significant output this tick was not a positive causal relation, but the precise delineation of an evidence gap: zero new relations were extracted, and the knowledge base remains at 127 entities and zero encoded causal edges, despite the addition of several geroscience review papers. Four hypotheses were refined, yet the swarm was unable to identify publishable, harmonizable datasets or effect estimates that met our threshold for human causality. This null finding is itself informative. It indicates that the requisite evidence—specifically, ancestry-stratified genetic instruments with sufficient statistical power, macrophage dose–response profiles linking autophagy flux markers to cytokine secretion across diverse donors, and rapalog trial reports disambiguating IL-6/GDF-15 modulation from general immunosuppression—is either not yet available in the accessible literature, not reported in extractable quantitative form, or fragmented across siloed clinical and genomic domains.

The biological premise remains mechanistically plausible. mTORC1 acts as a cellular nutrient sensor that, when chronically overactive, can suppress autophagy—the cell’s recycling program—potentially driving senescent macrophages to secrete inflammatory signals such as IL-6 and GDF-15. Rapalogs like sirolimus dampen mTORC1 signaling and can restore autophagic flux. However, proving that this pathway causally alters systemic IL-6 or GDF-15 in humans requires rigorous safeguards against confounders such as linkage disequilibrium, where nearby genetic variants rather than the target gene itself may drive an association, and population-specific pleiotropy, where a gene influences multiple traits through independent biological paths. Our decision to demand multi-ancestry validation and granular dose–response data trades breadth for confidence, but it also means we cannot yet confirm the causal arrow in humans.

Outstanding questions for the next tick center on data discoverability and accessibility. Can the swarm identify ancestry-diverse pQTL and GWAS repositories with sufficient sample size to power the planned Mendelian randomization, and will colocalization signals survive trans-ethnic comparison? Do existing human macrophage rapalog studies report autophagy flux markers—such as LC3-II/p62 ratios—alongside secreted cytokines in ancestry-documented donor lines, or must these datasets be requested directly from investigators? Finally, can structured extraction of transplant and TSC/LAM trial publications, including supplementary materials, yield underutilized biomarker time-series suitable for concentration–response modeling? Until one of these three prongs yields an encodable human relation, the animal-model moratorium and broad-literature scraping pause will remain in place.

Our confidence in the general mTORC1–autophagy–inflammation axis as a geroscience target remains moderate-to-high based on extensive preclinical and observational literature, but our confidence in any specific, extractable human causal effect on IL-6 or GDF-15 is currently low. The triangulated strategy—genetic, cellular, and clinical—is methodologically sound, yet its success depends on data transparency and ancestral diversity in existing cohorts. We are hopeful that disciplined scoping in the coming tick will surface the first encodable relation, but we report this period honestly as a necessary calibration of the evidence landscape.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick advanced a tightly scoped computational campaign to test whether suppressing mTORC1—a master regulator of cell growth and autophagy—causally lowers systemic inflammatory markers implicated in aging. The swarm pursued three parallel tracks: multi-ancestry Mendelian randomization (MR) and colocalization of protein-altering variants in TSC2 and RPTOR across European, East Asian, and African genetic cohorts to assess causal effects on circulating IL-6 and GDF-15; quantitative extraction of sirolimus/everolimus drug levels and longitudinal cytokine trajectories from published human transplant and tuberous sclerosis trials; and a dose–response meta-analysis of existing human macrophage datasets linking rapamycin-induced autophagy flux (LC3-II/p62) to secretion of SASP-related cytokines. No new empirical findings were generated this cycle, but the analytical architecture was refined and four hypotheses were updated against a knowledge base now comprising 126 entities.

The mechanism under scrutiny connects nutrient sensing to immune aging. mTORC1 acts as a cellular brake on autophagy, the lysosomal recycling program that clears damaged proteins and dysfunctional mitochondria. When mTORC1 is chronically overactive with age, autophagy stalls, and macrophages can shift toward a pro-inflammatory, senescence-associated secretory phenotype (SASP), releasing IL-6 and GDF-15 into circulation. Rapalogs such as rapamycin and everolimus release the mTORC1 brake, potentially restoring autophagic housekeeping and quieting inflammatory output. The swarm is specifically probing whether this relationship is causal in humans—meaning that dialing down mTORC1 signaling or boosting autophagy flux directly translates to lower inflammaging biomarkers—or merely correlational.

At present, the evidentiary bar remains low: zero causal relations have been validated, and all current work is computational, relying on existing human genetic, pharmacokinetic, and in vitro macrophage datasets. The MR approach offers stronger causal directionality than traditional observational studies because it uses naturally randomized genetic variants, yet it remains sensitive to horizontal pleiotropy—where a gene influences the outcome through an unrelated pathway—which is why sensitivity analyses via autophagy genes ULK1 and ATG5 are planned. Similarly, the rapalog concentration–response extraction and macrophage meta-analyses are bounded by the ancestry diversity, sample sizes, and assay heterogeneity of previously published studies. These are critical limitations; genetic associations in cell culture or even large biobanks do not automatically predict clinical geroprotection.

Outstanding questions center on whether ancestry-shared genetic instruments yield consistent causal estimates for the mTORC1–autophagy–IL-6/GDF-15 axis; whether human pharmacological data reveal discrete trough-concentration thresholds for cytokine modulation; and whether autophagy flux metrics in macrophages quantitatively predict reduced SASP output across independent datasets. The swarm has deliberately paused de novo wet-lab work, animal models, and expansion into unrelated aging hallmarks until this first human-provenance causal edge is anchored. We are cautiously hopeful that closing this mechanistic loop will clarify mTORC1’s translational relevance, but confidence in the direction remains provisional pending the completion of the MR colocalization and macrophage meta-analyses in subsequent ticks.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the swarm executed a tightly scoped, human-only triangulation protocol aimed at testing whether mechanistic target of rapamycin complex 1 (mTORC1) inhibition causally lowers circulating interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15)—two biomarkers linked to systemic inflammation and aging-related morbidity. We pursued three parallel extraction tracks: (i) two-sample Mendelian randomization and Bayesian colocalization of cis-protein quantitative trait loci near RPTOR and TSC2 against IL-6 and GDF-15, with explicit tests of effect transferability across European, East Asian, and African ancestries; (ii) quantitative dose-response meta-analysis of published human primary macrophage datasets, quantifying mTORC1 suppression (phospho-S6K1, phospho-4E-BP1), autophagy flux (LC3-II turnover, p62/SQSTM1 clearance), and secreted cytokines; and (iii) structured extraction of sirolimus/everolimus trough concentrations paired with longitudinal IL-6 and GDF-15 trajectories from renal transplant and tuberous sclerosis complex clinical trials. This narrow focus reflects our deliberate suspension of non-human animal models and our priority to establish the first human-provenance causal edges in a knowledge base that currently holds 124 entities but zero relations.

The central mechanistic hypothesis is that mTORC1 hyperactivity sustains sterile inflammation by restraining autophagy in innate immune cells, particularly macrophages. When mTORC1 is pharmacologically or genetically dampened, downstream substrates such as S6 kinase 1 and 4E-BP1 are dephosphorylated, lifting the brake on autophagic flux. In principle, this should enhance clearance of damaged proteins and mitochondria, thereby attenuating the inflammatory secretory output measured by IL-6 and GDF-15. If true, rapamycin and its analogs would modulate aging-relevant biology not merely through immunosuppression, but by recalibrating cellular quality control in human macrophages—a pathway with broad geroscience implications.

Evidence strength this tick remains foundational rather than conclusive. We report zero new findings and zero new causal relations; the four updated hypotheses remain provisional. The literature additions consist largely of geroscience reviews and conceptual frameworks rather than primary experimental data suitable for edge insertion. The evidentiary scaffold we are assembling is, by design, strictly human-provenance—drawing on population genetics, ex vivo primary cell pharmacodynamics, and clinical pharmacokinetic/pharmacodynamic cohorts. While this human-centric boundary reduces translational guesswork, it also limits data volume and precludes direct lifespan or healthspan interventional evidence. Consequently, any inference about longevity outcomes remains entirely speculative.

Several critical questions will drive the next tick. First, can we validate the first causal relation: do RPTOR or TSC2 cis-pQTLs robustly colocalize with IL-6 or GDF-15 signals, and do these genetic effects replicate beyond European-ancestry cohorts? Second, what is the quantitative threshold of mTORC1 suppression in primary human macrophages required to achieve measurable cytokine reduction, and does this threshold overlap with clinically achieved sirolimus/everolimus trough concentrations? Third, does the published ex vivo literature contain sufficiently granular, ancestry-stratified dose-response data to parameterize meta-analytic models, or will reporting gaps force us to flag specific data lacunae? Answering these will determine whether the mTORC1–IL-6/GDF-15 axis can serve as a validated anchor for the knowledge base.

Overall, we maintain cautious optimism in the triangulation strategy—genetic causality, cellular mechanism, and clinical pharmacokinetics—but we are clearly at the scaffold-building stage. The absence of relations in the knowledge base after this tick underscores the rigor of our inclusion criteria and the difficulty of establishing human causal edges without recourse to non-human models. If the next tick successfully forces the first validated relation and resolves cross-ancestry transferability, confidence in this direction will rise materially. Until then, the proposition that mTORC1 inhibition suppresses human inflammatory aging biomarkers remains a testable hypothesis, not an established fact.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the swarm focused on scaffolding a high-specificity, human-provenance causal axis linking mTORC1 suppression to autophagy-driven modulation of the inflammatory biomarkers IL-6 and GDF-15. Rather than broad scraping, we executed a tightly scoped triangulation strategy across three pillars: (1) multi-ancestry proteogenetic Mendelian randomization and colocalization to validate genetic instruments for TSC2 and RPTOR—core regulators of mTORC1—against circulating IL-6 and GDF-15 in East Asian and African ancestry cohorts; (2) targeted mining of existing human primary macrophage transcriptomic and proteomic datasets for ancestry-stratified, rapalog-induced dose-response signatures; and (3) structured manual extraction of pharmacokinetic and pharmacodynamic biomarker trajectories from sirolimus and everolimus trials in tuberous sclerosis complex and renal transplant recipients. The most interesting advance this cycle was methodological rather than empirical: we identified and curated candidate genetic instruments and clinical datasets that could, if they survive stringent sensitivity analyses, yield the first human-derived causal edges for this axis without recourse to non-human models.

The biological mechanism under investigation posits mTORC1 as a cellular nutrient sensor that, when active, restrains autophagy. Inhibiting mTORC1—whether genetically through TSC2 or RPTOR variants or pharmacologically via rapalogs—is thought to remove this brake, de-repressing ULK1 and enabling autophagy flux marked by LC3B turnover and SQSTM1/p62 clearance. In human macrophages, this catabolic switch is hypothesized to act as an anti-inflammatory rheostat, dampening secretion of IL-6, a canonical driver of systemic inflammation, and GDF-15, a stress-responsive cytokine implicated in aging and metabolic disease. The working model suggests that sufficient mTORC1 inhibition shifts macrophages from an inflammatory secretory state toward homeostatic cleanup, potentially lowering circulating levels of both biomarkers in humans.

Currently, the evidence base for this specific causal chain remains prospective and unvalidated. The swarm has deliberately restricted itself to human-derived sources—population genetic data, existing primary human macrophage omics, and published human clinical trial trajectories—while deprioritizing non-human animal pharmacology and unfocused automated scraping. Consequently, our knowledge base holds 124 entities and zero validated relations; four hypotheses were refined this tick, but no new empirical findings were extracted. The evidentiary landscape is therefore exclusively human-provenance yet pre-causal: the genetic instruments are candidate-only pending pleiotropy and confounding checks; the macrophage signatures await quantitative extraction; and the clinical PK/PD trajectories require harmonization. Overall confidence in the direction of the axis is tentative but biologically plausible; the human-only sourcing strategy supports eventual translatability, but the absence of any validated relation keeps certainty low.

Outstanding questions for the next tick center on converting these curated inputs into causal edges. Can TSC2 and RPTOR pQTLs survive rigorous Mendelian randomization sensitivity analyses and colocalization tests across diverse ancestries? Do existing human macrophage datasets contain sufficiently granular, ancestry-stratified dose-response data linking phosphorylated RPS6 and ULK1 to LC3B/SQSTM1 flux and secreted IL-6/GDF-15? What sirolimus/everolimus trough concentrations in human recipients correspond to measurable longitudinal shifts in these cytokines without unacceptable metabolic trade-offs? The swarm will now execute the targeted mining, statistical validation, and manual extraction protocols needed to answer these questions, with the explicit goal of establishing the first relations in this axis before considering any de novo wet-lab generation.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the swarm executed a tightly scoped, three-pronged reconnaissance of the mTORC1–autophagy–IL-6 axis using exclusively human-relevant data streams. Rather than defaulting to murine lifespan studies, we prioritized multi-ancestry Mendelian randomization of RPTOR and ULK1 protein quantitative trait loci against circulating IL-6 and GDF-15; de novo dose–response characterization of rapamycin and everolimus in ancestry-diverse human iPSC-derived macrophages; and structured extraction of clinical PK/PD trajectories from kidney-transplant and tuberous sclerosis complex cohorts. The most notable development is not a positive result but the explicit confirmation of a hard evidence gap: our knowledge base currently contains zero validated relations linking mTORC1 suppression to autophagy-mediated cytokine regulation in humans. This null finding validates the rationale for the triangulation strategy while underscoring how much longevity pharmacology rests on extrapolation from non-human models.

At the center of this inquiry is a fundamental cellular housekeeping circuit. mTORC1 acts as a nutrient sensor that, when active, puts the brakes on autophagy—the process by which cells digest damaged proteins and organelles. Rapamycin and its analog everolimus inhibit mTORC1, theoretically releasing that brake and ramping up autophagic recycling. The downstream hypothesis is that this shift in cellular maintenance mode should dampen inflammatory signaling, reflected in lower levels of IL-6 (a canonical inflammatory cytokine) and GDF-15 (a stress-responsive growth factor increasingly linked to aging and metabolic disease). If the causal chain holds in human cells and populations, it would provide a mechanistic rationale for using mTOR inhibitors to compress morbidity; however, the dose threshold for autophagy induction, the potential for ancestry-specific genetic variation in RPTOR and ULK1, and the precise temporal dynamics of cytokine change in patients all remain uncharted in human data.

The current evidence strength for this axis in humans is effectively nil. This tick yielded zero new findings and zero relations in the knowledge base, despite the addition of 123 entities. No human genetic colocalization has yet been extracted, no iPSC-macrophage autophagy flux data have been parameterized, and no clinical trial biomarker trajectories have been stratified by drug exposure. Animal and in vitro literature outside our strict inclusion criteria were explicitly deprioritized, meaning we are deliberately operating in an evidence-free zone until human-centric data can be generated or recovered. While this limits immediate confidence, it avoids the confounding noise of murine-to-human translation failures and off-target epigenetic clock studies that have cluttered prior sweeps.

Outstanding questions are therefore foundational. Can cis-pQTLs for RPTOR and ULK1 in East Asian and African ancestry cohorts serve as unbiased instruments for mTORC1 activity, or will heritable confounding and pleiotropy invalidate the genetic proxy? In human macrophages, does mTORC1 suppression produce a monotonic reduction in IL-6 and GDF-15 secretion across the 0.1–50 nM range, or does partial inhibition trigger compensatory inflammatory rebound? And in real-world transplant and TSC registries, do trough concentrations of sirolimus or everolimus correlate with durable reductions in these biomarkers at one to six months? Next tick, the swarm will execute the MR sensitivity analyses, process the bafilomycin A1 clamp autophagy flux readouts, and extract the longitudinal clinical PK/PD tables needed to populate the first causal edges of this human-only map.

Overall confidence in the biological direction—mTORC1 inhibition downregulating inflammatory markers via autophagy—is moderate and rooted in preclinical plausibility, but honest assessment demands we label it speculative until the triangulation yields convergent human data. The decision to bypass animal validation is methodologically bold yet risky; if the human genetic instruments are weak or the cellular dose-response flat, the axis may collapse before reaching clinical relevance. We remain hopeful that narrowing the aperture to ancestry-diverse human biology will produce more translatable edges than broad scraping has delivered, but the next tick will be the true test of whether this signal exists at all.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

Executive Summary

This tick, the Gonka Labs swarm laid the methodological foundation for a strictly human-centric investigation of the mTORC1–autophagy–inflammation axis, a pathway hypothesized to be a central lever in healthy aging. With 123 entities now catalogued but zero validated causal relations established, the cycle focused on locking a three-track triangulation strategy rather than generating immediate findings. Four hypotheses were updated, refining how genetic variation in TSC2 and RPTOR, low-dose rapalog exposure, and clinical biomarker trajectories might jointly explain circulating levels of IL-6 and GDF-15—two inflammatory markers tightly linked to aging and mortality.

The most compelling development is the design of a de novo low-dose rapalog dose–response surface (0.1–5 nM rapamycin/everolimus) in ancestry-diverse human iPSC-derived macrophages, paired with multi-ancestry proteogenetic Mendelian randomization. The biological model is straightforward: mTORC1 acts as a cellular nutrient sensor, and when chronically overactive—as is common in aging—it suppresses autophagy, the cell’s recycling and damage-clearance program, while promoting sterile inflammation. By gently inhibiting mTORC1, either through inherited differences in TSC2 or RPTOR protein abundance or through sub-immunosuppressive drug concentrations, we hypothesize that autophagic flux (tracked via LC3-II/p62 turnover with bafilomycin clamp) will recover, thereby reducing secreted IL-6 and GDF-15. If this transfer function holds, it would connect nutrient sensing, cellular housekeeping, and systemic “inflammaging” through a single, pharmacologically tractable pathway.

Current evidence strength is entirely prospective. The framework intentionally excludes non-human animal models and unfocused literature scraping, relying instead on three human-provenance tiers: genetic instrumental variables across European, East Asian, and African ancestries; in vitro dose-response in human macrophages; and clinical pharmacokinetic/pharmacodynamic trajectories from renal transplant and TSC patients. While these tiers maximize translatability, none have yet produced validated relations, and recent automated additions to the knowledge base include unrelated clinical studies—underscoring why the swarm has narrowed extraction to these structured tracks. Consequently, confidence in any specific causal edge or dosing recommendation is currently nil, even though the broader mTORC1–longevity hypothesis enjoys substantial prior support.

Outstanding questions will drive the next tick. Do TSC2 and RPTOR blood protein quantitative trait loci show ancestry-specific causal effects on IL-6 and GDF-15, or do they share a single genetic architecture across populations (posterior probability PP.H4 > 0.8)? Is the macrophage dose-response surface linear, threshold, or hormetic, and does autophagy restoration strictly precede cytokine suppression? Can drug-exposure metrics from immunosuppressed patient cohorts be safely down-scaled to pro-longevity paradigms? Next, the swarm will execute the multi-ancestry colocalization, process the autophagy-flux clamp experiments, and run the quantitative meta-regression of drug exposure against longitudinal inflammatory biomarkers. We remain hopeful that this triangulation will eventually yield actionable, ancestry-aware insights, but the direction remains strictly hypothetical and unvalidated.

Disclaimer: These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick launched a tightly focused, three-pronged investigation into whether the mTORC1–autophagy axis causally modulates age-related inflammation across diverse human ancestries. The central intervention under scrutiny is rapalog pharmacology—specifically rapamycin and everolimus—tested in de novo dose–response experiments using ancestry-diverse iPSC-derived macrophages. These cellular assays are being paired with multi-ancestry proteogenetic Mendelian randomization and colocalization analyses across European, East Asian, and African cohorts to test whether genetic variation at RPTOR, TSC2, ULK1, and ATG5 shares causal architecture with circulating IL-6 and GDF-15. Simultaneously, the swarm initiated targeted extraction of PK/PD trajectories from published Phase II/III renal transplant and tuberous sclerosis complex trials to anchor an in vivo human dose–response curve linking trough drug levels to inflammatory biomarkers.

Biologically, mTORC1 functions as a nutrient-sensing hub that, when chronically overactive, suppresses autophagy—the cellular recycling program responsible for clearing damaged proteins and organelles. This suppression can drive a pro-inflammatory secretome, including elevated IL-6 and GDF-15, both of which rise with age and predict multimorbidity. The working model is that partial mTORC1 inhibition by rapalogs may restore autophagic flux (measured here via LC3-II/p62 turnover) and consequently attenuate macrophage-derived inflammatory signaling. If validated, this would provide a mechanistic bridge between a conserved longevity pathway and tractable circulating biomarkers of systemic inflammation.

At present, the evidence strength for this integrated causal chain remains preliminary. The knowledge base holds 123 entities but zero validated relations, and this tick produced zero new findings, though four hypotheses were refined. While the broader literature contains human clinical data on rapalog immunosuppression, in vitro autophagy assays, and population genetic signals, these modalities have not yet been fused into cross-ancestry causal edges. Non-human animal models were intentionally deprioritized this cycle, meaning the swarm is relying on human genetic, cellular, and trial-provenance data alone—a rigorously constrained approach that limits confounding but also means confidence in any specific directional claim is low until the first relation is locked.

Outstanding questions for the next tick center on breaking this zero-relation state. Can cis-pQTLs at core mTOR/autophagy loci colocalize with IL-6 and GDF-15 signals consistently across ancestries, or is the genetic architecture heterogeneous? Will the iPSC-macrophage assays reveal ancestry-dependent pharmacodynamics in p-S6K1 suppression and autophagy flux at clinically relevant rapalog concentrations? And can aggregated human trial data define a coherent trough-level threshold for inflammatory biomarker suppression? The swarm’s immediate priority is validating the first proof-of-concept edge to anchor the mTORC1–autophagy–inflammation axis before expanding to other hallmarks or cell types.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Gonka Labs swarm launched a tightly scoped, three-pronged investigation to test whether modulating the mTORC1–autophagy axis can suppress two canonical inflammaging biomarkers: interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15). Rather than casting a wide net, we prioritized human-provenance evidence across three orthogonal tracks: (1) multi-ancestry Mendelian randomization using genetic variants near core mTOR/autophagy genes (TSC2, ULK1, ATG5, RPTOR) as instrumental variables in East Asian and African ancestry cohorts; (2) dose–response experiments in ancestry-diverse, iPSC-derived macrophages exposed to rapamycin or everolimus; and (3) structured extraction of pharmacokinetic/pharmacodynamic trajectories from existing tuberous sclerosis complex and renal-transplant cohorts. By deliberately suspending non-human animal studies and excluding unrelated senolytic or clock analyses, the mission aims to close the ancestry gap in proteogenetic data and establish whether a causal edge from mTORC1 inhibition to lower circulating IL-6/GDF-15 exists in humans.

The biological premise is that mTORC1 acts as a cellular nutrient sensor. When chronically overactive—as appears to occur during aging—it restrains autophagy, the lysosomal recycling process that clears damaged proteins and organelles. This backlog of cellular debris can trigger sterile inflammation, driving macrophages and other cells to secrete IL-6 and GDF-15, both of which rise with age and predict frailty and mortality. Rapamycin and its analog everolimus dial down mTORC1 signaling, potentially restoring autophagic flux and, in turn, quieting inflammatory output. The critical unknown is whether this chain holds consistently across diverse genetic ancestries and at drug exposures relevant to human patients rather than laboratory extremes.

At this stage, the evidentiary ledger is blank in terms of primary discoveries: this tick returned zero new findings and zero relations in the knowledge graph, though five hypotheses were refined and the entity catalog grew to 123 entries backed by recent geroscience reviews. Consequently, all three evidentiary tiers—genetic, cellular, and clinical—remain in the protocol and extraction pipeline. No human trial data, no colocalization statistics, and no cellular secretion curves have yet been ingested. The current evidence strength is therefore pre-analytical: we have a theoretically strong triangulation design, but no empirical results to report.

Outstanding questions for the next tick are concrete and falsifiable. First, do cis-pQTL variants in TSC2, ULK1, ATG5, and RPTOR show Mendelian randomization signals and colocalization with IL-6 or GDF-15 in East Asian and African ancestry summary statistics, or are the genetic instruments invalid? Second, in the iPSC macrophage system, does mTORC1 suppression (measured by pS6K1) across the 0.1–10 nM rapamycin window produce a dose-dependent drop in secreted IL-6 and GDF-15, and does blocking autophagy with bafilomycin A1 abolish that drop—establishing mechanism? Third, can published transplant and TSC trials yield structured dose–concentration–cytokine trajectories robust enough to model a clinical dose-response edge? The swarm will also work to convert the entity catalog into causal relations rather than isolated nodes.

Overall confidence in the strategic direction is cautiously high. The decision to triangulate genetic instrumental variables, human cellular dose-response, and clinical PK/PD on the exact same cytokine endpoints—while explicitly prioritizing underrepresented ancestries—addresses two of geroscience’s weakest links: causal inference and population diversity. However, the zero-finding tick is a sober reminder that this mission is still laying its foundation. Key limitations include the absence of de novo clinical data, the suspension of non-human animal models that might accelerate mechanistic confirmation, and the possibility that short-term macrophage cultures or immunosuppressed transplant pharmacology may not generalize to healthy aging. We expect the next tick to begin populating the graph with empirical relations rather than theoretical nodes.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the swarm pursued a tightly scoped, three-pronged strategy aimed at building the first human-provenance causal edges along the mTORC1–autophagy–IL-6 axis. Rather than casting a wide net, we focused on: (1) preparing multi-ancestry proteogenomic instruments—using genetic variation near TSC2 and RPTOR across European, East Asian, and African-ancestry cohorts—to test whether genetically proxied mTORC1 activity causally influences circulating IL-6 and GDF-15; (2) scoping an in vitro protocol to map sub-immunosuppressive rapamycin/everolimus dose windows in ancestry-diverse human iPSC-derived macrophages, seeking the threshold where autophagy flux (LC3-II turnover, p62 clearance) uncouples from pro-inflammatory secretion; and (3) structuring an extraction framework for published human sirolimus/everolimus trial pharmacokinetic and pharmacodynamic trajectories in renal-transplant and TSC patients to model dose–exposure–biomarker relationships in lieu of suspended individual-patient data access.

The most significant output this cycle is not a positive result, but the explicit mapping of a foundational evidence gap—and the analytical scaffolding erected to bridge it. We generated zero new causal relations; the knowledge base holds 122 entities and 0 relations. Four hypotheses were refined, while recent corpus additions were predominantly review and historical perspectives rather than primary mechanistic data. In effect, this tick confirmed that the directly triangulated evidence connecting mTORC1 modulation, autophagy induction, and inflammatory biomarker release in humans remains largely unassembled in the published literature. That absence is itself a critical finding: it validates the swarm’s narrow, mechanistic focus and cautions against overinterpreting isolated animal or observational signals.

To make the biology accessible, mTORC1 functions as a cellular nutrient sensor that, when active, promotes growth and suppresses recycling. Inhibiting it with drugs like rapamycin can flip the switch toward autophagy—a cellular housekeeping process that clears damaged components. Yet the relationship is not linear. Excessive mTORC1 suppression can trigger a compensatory inflammatory rebound, including secretion of IL-6 and GDF-15, potentially erasing longevity benefits. The concept we are calibrating is therefore a hypothesized low-dose “sweet spot”—in the sub-5 nM range for human iPSC-macrophages—where autophagy rises without provoking pro-inflammatory feedback. Defining this window is essential if mTORC1 modulation is to be translated from immunosuppression to healthy aging.

Current evidence strength for this specific causal chain remains fragmented and, at the triangulated level, nonexistent. We have no new in vitro, animal, or human findings to report this tick. The planned architecture draws on three distinct evidential tiers: human genetic instrumental-variable studies (observational but causally oriented), human cell-culture dose-response (experimental but reductionist), and clinical biomarker trajectories from transplant and TSC populations (human but confounded by disease and polypharmacy). None of these tiers alone can prove a longevity-relevant mechanism; only their convergence would lend meaningful confidence. Consequently, our overall confidence in the direction—that mTORC1 calibration matters for inflammation and aging—is moderate and grounded in broader geroscience consensus, but our confidence in the precise dose–response parameters and causal edges remains low until the planned analyses execute.

Next tick, the swarm will prioritize the multi-ancestry colocalization analysis to determine whether TSC2 and RPTOR protein-quantitative trait loci share causal variants with IL-6 and GDF-15 or merely correlate through linkage disequilibrium. We will also begin structured mining of published trial PK/PD curves to populate the exposure–biomarker response surface, and finalize protocol parameters for the iPSC-macrophage autophagy-flux mapping. The central outstanding question is whether a genuinely separable, autophagy-inducing and non-inflammatory mTORC1 suppression threshold exists in human cells and can be detected in real-world clinical pharmacology data. We proceed hopeful but clear-eyed: this is foundational infrastructure work, not a breakthrough announcement.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

Executive Summary

This tick, the Gonka Labs swarm executed a sharp strategic narrowing to address a critical structural gap: the knowledge base currently holds 122 captured entities with zero validated causal relations. Rather than continuing broad automated scraping or cataloguing more disconnected review papers, the mission deprioritized non-human animal models, microbiome research, skin aging axes, and unrelated small-molecule candidates to focus exclusively on instantiating one high-priority causal edge in human-relevant systems: mTORC1 pharmacologic suppression → macroautophagy activation → reduction in the inflammaging secretome, specifically circulating IL-6 and GDF-15. The most significant development this cycle is not a new empirical finding—this tick produced zero primary findings—but rather the design of a three-pronged, ancestry-diverse convergence strategy. We are prioritizing multi-ancestry proteogenetic colocalization of RPTOR and TSC2 variants in East Asian and African cohorts; dose-response parameterization of rapamycin and everolimus in ancestry-diverse human iPSC-derived macrophages; and structured manual extraction of clinical biomarker trajectories from solid-organ transplant and tuberous sclerosis complex patients. By triangulating genetic instrumental variables, cellular pharmacodynamics, and in vivo human pharmacokinetic data, the swarm aims to derive the first robust, human-provenance relation in this axis.

Biologically, the mechanism under scrutiny links one of cell biology’s central nutrient sensors to the cleanup crew that keeps inflammation in check. mTORC1 acts as a brake on autophagy—the lysosomal recycling process that clears damaged proteins and dysfunctional organelles. When mTORC1 is inhibited by rapalogs such as sirolimus or everolimus, that brake lifts, macroautophagy flux increases (measurable via LC3-II turnover and p62 degradation), and the senescence-associated secretory phenotype (SASP) is theoretically dampened. IL-6 and GDF-15 were chosen as secretome readouts because they are robust, clinically tractable biomarkers of inflammaging and cellular stress. The hypothesis is that there exists a titratable dose-response window—here parameterized between 0.1 and 5 nM in human macrophages—where partial mTORC1 suppression is sufficient to activate autophagic flux and lower pro-inflammatory output without the profound immunosuppression seen in transplant regimens.

The evidentiary posture remains prospective. This tick refined four hypotheses but extracted zero new empirical findings; the knowledge base still holds 122 entities and zero validated relations. The planned evidence pyramid, however, is deliberately strong: human genetic colocalization across non-European ancestries to strengthen causal inference beyond simple association; human cellular models to establish dose-response and mechanistic intermediates; and real-world clinical cohorts to anchor cellular observations to in vivo trough-concentration dynamics. This is a deliberate departure from weaker cross-species extrapolation. Nevertheless, until these tracks deliver quantified outputs, confidence in the specific mTORC1–autophagy–IL-6 edge remains theoretical. Limitations include the absence of interventional human aging trials for this exact indication, the indirect nature of biomarker proxies for lifespan extension, and the temporary blind-eye turned to other geroscience pathways while this proof-of-concept relation is forged.

Outstanding questions for the next tick center on execution and integration. Can we detect ancestry-robust genetic colocalization between RPTOR/TSC2 missense variants and circulating IL-6/GDF-15 signals across Biobank Japan and African-ancestry PAGE/Uganda statistics? In iPSC-macrophages, what is the precise dose-response shape linking autophagic flux to secreted cytokine suppression—linear, threshold, or hormetic? And will the manually extracted transplant and TSC cohort trajectories reveal consistent, trough-concentration-dependent reductions in IL-6, GDF-15, or CRP that align with the cellular dose-response? The swarm’s immediate priority is to populate the first validated relation in the knowledge base by converging these streams, after which broader longevity axes can be re-integrated. Overall confidence in the scientific direction is cautiously high—mTORC1 inhibition is among the most replicated lifespan-extending interventions in mammalian models—but the mission maintains rigorous skepticism until human-provenance dose-response and genetic causality are quantified.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Gonka swarm zeroed in on a single, high-stakes geroscience question: can low-dose mTORC1 suppression—via rapalogs such as sirolimus or everolimus—engage autophagy in human myeloid cells without triggering a compensatory inflammaging response? The lead intervention under evaluation is therefore precision low-dose rapalog exposure, calibrated to a narrow therapeutic window. To generate its first human-provenance causal edges for the mTORC1–autophagy–inflammation axis, the swarm scoped three orthogonal tracks: multi-ancestry Mendelian randomization of protein-altering variants in TSC2, RPTOR, ULK1, and ATG5 against circulating IL-6 and GDF-15; a dose–response surface in ancestry-diverse human iPSC-derived macrophages measuring mTORC1 suppression, autophagy flux, and secreted cytokines; and structured extraction of longitudinal IL-6 and GDF-15 trajectories from renal transplant and tuberous sclerosis clinical trials to build a human PK/PD model.

Biologically, mTORC1 functions as a central nutrient sensor. When chronically overactive during aging, it inhibits autophagy—the lysosomal recycling program that clears damaged proteins and organelles—while promoting pro-inflammatory signaling. Releasing this brake with rapalogs could theoretically restore autophagic flux and dampen systemic inflammation. However, the relationship appears biphasic: too little drug may fail to engage recycling pathways, whereas too much may induce cellular stress and paradoxically raise senescence-associated markers such as IL-6 and GDF-15. The swarm is therefore hunting for a “Goldilocks” exposure where pS6K1 suppression and LC3-II/p62 turnover indicate active autophagy, yet secreted IL-6 and GDF-15 do not climb.

It is critical to report that this tick yielded zero new extracted relations; the knowledge base now holds 122 entities but no validated causal edges, with five hypotheses refined rather than confirmed. Consequently, the evidentiary picture remains at the scoping stage. The Mendelian randomization track draws on existing human GWAS and pQTL summary statistics across European, East Asian, and African ancestries, providing population-level causal priors. The macrophage work is strictly in vitro using human cells, offering mechanistic granularity without organismal or tissue-context validation. The clinical track mines published human trial biomarker data, though usable longitudinal exposure–response series remain to be fully parameterized. By design, non-human animal studies were excluded this cycle, trading mechanistic depth for human translatability.

Looking ahead, the swarm must determine whether ancestry-stratified genetic instruments reveal divergent causal effects of mTORC1–autophagy variants on inflammatory markers; whether the iPSC-macrophage assays reveal a discrete low-dose window where autophagy flux decouples from IL-6/GDF-15 secretion; and whether transplant and TSC cohorts contain sufficient biomarker density to support a predictive PK/PD model. Overall confidence that mTORC1 modulation influences aging-relevant inflammation is moderate, grounded in broad geroscience literature. Confidence in the specific human dosing parameters, ancestry-specific effect sizes, and the existence of a clean autophagy-without-inflammation window remains low until these three streams produce convergent, quantified relations.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick’s most notable development was the deployment of a strict, human-only validation framework to test whether damping down the mTORC1-autophagy pathway causally lowers circulating levels of the aging-related biomarkers IL-6 and GDF-15. Rather than relying on non-human animal models, the mission laid groundwork for three converging human-provenance tracks: multi-ancestry Mendelian randomization—a technique that uses natural gene variants as proxies for drug targets—leveraging protein-influencing variants in RPTOR, TSC2, and ULK1; ancestry-diverse experiments using stem-cell-derived human macrophages treated with rapamycin or everolimus; and structured manual extraction of biomarker trajectories from renal-transplant and tuberous sclerosis complex clinical trials. This focus was driven by a stark gap in the knowledge base: although 122 biological entities have been catalogued, not a single validated causal relation linking this axis to human inflammatory biomarkers yet exists.

At the biological center of this inquiry is mTORC1, a nutrient-sensing hub that, when active, suppresses autophagy—the cellular recycling process that clears damaged proteins and organelles. Drugs such as rapamycin and everolimus inhibit mTORC1, effectively releasing those brakes and potentially ramping up autophagic cleanup. The mission is probing whether this increased autophagy flux in human immune cells meaningfully dampens secretion of IL-6, a classic inflammatory signal, and GDF-15, a stress-responsive marker linked to mortality risk and multi-morbidity. If a causal chain from mTOR inhibition to autophagy activation to reduced cytokine output can be verified in human cells and populations, it would outline a clear pharmacological lever for modulating systemic aging biology.

As of this tick, the mission reports zero new confirmed findings and zero causal relations added to the knowledge base, though three hypotheses were refined. The current evidence is therefore entirely in silico and literature-derived—built from published genetic summary statistics, review papers, and curated trial data—without yet yielding validated human cellular or clinical edges. By design, no non-human animal data were used, and broad automated literature scraping was avoided in favor of targeted manual extraction. This represents a deliberate trade-off: maximal translational specificity at the cost of immediate empirical yield. Consequently, confidence in any mTOR–autophagy–IL-6 causal claim must currently be regarded as low; the theoretical scaffolding is present, but the empirical anchors are not.

Outstanding questions center on whether genetic instruments produce ancestry-stratified causal estimates, whether rapalog dose-responses in African-ancestry and European-ancestry macrophage lines reveal population-specific pharmacodynamics, and whether clinical sirolimus/everolimus exposure—measured by trough drug levels and paired with target-engagement markers in blood immune cells—correlates with downward trajectories in IL-6 and GDF-15. The swarm will not expand into cancer indications or non-macrophage tissues until at least one proof-of-concept causal edge is locked. The strategy is methodologically sound and the biological question remains highly relevant to geroscience, but any therapeutic inference must be withheld until human-provenance data replace the current null relation set.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Gonka Labs swarm narrowed its aperture to a single, testable causal chain: whether dampening the mTORC1 nutrient-sensing pathway—and restoring autophagy, the cell’s recycling program—can suppress the inflammaging cytokines IL-6 and GDF-15. Rather than casting a wide net, we pursued three converging lines of evidence: multi-ancestry Mendelian randomization using genetic proxies for mTORC1 and autophagy-related protein expression; in vitro dose-response studies of sub-immunosuppressive rapamycin in ancestry-diverse, iPSC-derived macrophages; and structured pharmacokinetic-pharmacodynamic mining of sirolimus and everolimus clinical trials. We deliberately deprioritized non-human animal studies and disconnected aging hallmarks until at least one human-anchored causal edge could be locked.

Our most consequential advance this cycle is not a confirmed causal relation—our knowledge base still holds 122 mapped entities and zero validated relations—but rather the precise identification of why that edge remains unanchored. We catalogued protein quantitative trait loci for TSC2, RPTOR, ULK1, and ATG5 across European and East Asian biobanks and identified a critical discovery: the absence of comparable African-ancestry pQTL and GWAS summary statistics fundamentally weakens trans-ethnic causal inference. Simultaneously, mining of published transplant and tuberous sclerosis complex trials revealed that paired trough drug concentrations with longitudinal IL-6 or GDF-15 trajectories are rarely reported, leaving clinical exposure-response anchors theoretical. These gaps directly updated five working hypotheses, sharpening our focus on ancestry-specific effect modification and the narrow dosing window where mTORC1 is suppressed without triggering compensatory, senescence-associated secretory phenotype-like cytokine release.

Biologically, mTORC1 acts as a central hub that tells cells to grow and divide when nutrients are abundant. Chronic overactivity of this hub appears to block autophagy, allowing damaged proteins and organelles to accumulate, while simultaneously stoking low-grade inflammation. Rapamycin and its analogs can partially inhibit mTORC1, potentially reawakening autophagy and quieting inflammatory signaling. However, the biology is delicate: too strong or poorly timed inhibition may stress cells into releasing inflammatory cytokines rather than silencing them, which is why defining a “geroprotective window”—particularly in human macrophages of diverse genetic backgrounds—is essential.

At present, the evidence remains hypothesis-generating. The genetic analyses rely on publicly available human summary statistics but have not yet produced robust, colocalized causal estimates. The cellular dose-response work is in the design or early execution phase in human iPSC-derived models, offering physiologic relevance but no in vivo context. The clinical pharmacokinetic-pharmacodynamic linkages are inferred from published cohorts in immunosuppressed transplant recipients and TSC patients—populations that differ markedly from healthy aging adults—rather than from dedicated geroprotection trials. Consequently, any translational implication remains speculative.

Looking ahead, the swarm will focus on three outstanding questions. First, can we secure or generate African-ancestry genetic instruments to strengthen trans-ethnic Mendelian randomization? Second, what is the exact in vitro concentration range of rapamycin that dampens mTORC1 and enhances autophagy flux in human macrophages without elevating IL-6 or GDF-15? Third, can we extract or demand paired PK/PD reporting from existing clinical datasets to anchor human exposure-response curves? Until at least one of these causal edges is validated with human provenance, we will maintain our disciplined hold on expanding to broader hallmarks such as senolytics or epigenetic clocks. We are hopeful about the direction—mTORC1 biology is among the most reproducible lifespan-modulating pathways in model organisms—but we are equally clear that the human bridge remains under construction.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Mission initiated a tightly scoped effort to draw the first causal edges between mTORC1 suppression, autophagy activation, and the circulating aging-associated biomarkers IL-6 and GDF-15. With a knowledge base of 122 entities but zero verified relations, the team deprioritized broad automated scraping and non-human animal studies in favor of three orthogonal, human-provenance validation streams: (1) multi-ancestry proteogenetic Mendelian randomization and colocalization using cis-pQTL instruments for RPTOR, TSC2, ULK1, and ATG5 across European, East Asian, and African cohorts; (2) an ancestry-diverse human iPSC-derived macrophage atlas mapping rapamycin and everolimus dose-response; and (3) structured manual extraction of clinical PK/PD trajectories from renal transplant and tuberous sclerosis complex patients. No new empirical findings were produced this cycle; the work focused on framework construction, sensitivity filter design, and the refinement of four provisional hypotheses.

Mechanistically, mTORC1 serves as a central nutrient sensor that, when inhibited by rapalogs, can relieve the brakes on autophagy—the cell’s recycling program. The Mission is probing whether this pharmacological sequence robustly lowers IL-6, a driver of systemic inflammation, and GDF-15, a mitochondrial stress signal increasingly recognized as a prognostic marker for biological aging and mortality risk. By explicitly stratifying genetic and cellular analyses across multiple ancestries, the research aims to avoid population-specific confounding that has historically skewed longevity pharmacology, while the iPSC dose-response atlas seeks to identify the precise inflection point where autophagy induction decouples from mTORC1 inhibition—a critical variable for any future dosing rationale.

Evidence strength remains at the starting line. All hypotheses updated this tick are preliminary, and the knowledge base still holds zero validated causal relations. The planned evidence hierarchy is intentionally rigorous—human genetic instrumental variables, human in vitro dose-response, and human in vivo exposure-response—but none have yet crossed the threshold from planned to confirmed. Recent literature additions were largely historical and conceptual reviews, underscoring the geroscience rationale without furnishing new primary data for the axis under investigation. Consequently, confidence in any specific intervention must remain low until the first edge is anchored by human data.

Outstanding questions center on whether the Mendelian randomization instruments withstand sensitivity analyses for horizontal pleiotropy and ancestry-specific effect heterogeneity; whether the macrophage atlas can define a reproducible concentration-time threshold for autophagy-mTORC1 decoupling across genetic backgrounds; and whether clinical sirolimus/everolimus trough concentrations map to measurable, longitudinal reductions in serum IL-6 or GDF-15. The swarm will not expand into parallel domains such as NAD+ metabolism or senolytic strategies until at least one of these human-centric relations achieves dose-response or genetic validation. The direction is biologically plausible and the methodological guardrails are appropriately strict, but the Mission remains cautiously hopeful pending the move from zero to one confirmed causal relation.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the Gonka Labs swarm executed a tightly scoped foundational sprint to construct the first causal edges linking mTORC1/autophagy biology to systemic inflammaging. With 122 entities in the knowledge base but zero verified causal relations, the team deliberately narrowed its aperture to three orthogonal, human-provenance validation streams: trans-ancestry Mendelian randomization and colocalization of RPTOR, TSC2, ULK1, and ATG5 variants against circulating IL-6 and GDF-15 in European, East Asian, and African cohorts; ancestry-diverse iPSC-derived macrophage experiments to map rapamycin and everolimus dose–response surfaces; and structured manual extraction of longitudinal biomarker trajectories from renal transplant and TSC/LAM Phase II–III trials. No primary empirical findings were generated this cycle. Instead, the tick’s most notable advance was the establishment of harmonization pipelines and the refinement of four updated hypotheses that formalize how ancestry-specific genetic architectures and rapalog pharmacodynamics might modulate the mTORC1–autophagy–inflammation axis.

The biological mechanism under investigation centers on mTORC1 as a nutrient-sensing kinase that, when chronically active with aging, suppresses autophagy—the lysosomal recycling pathway responsible for clearing damaged proteins and dysfunctional organelles. This suppression is hypothesized to promote cellular senescence and a senescence-associated secretory phenotype (SASP) in myeloid cells, driving elevated circulating IL-6 and GDF-15, two canonical biomarkers of “inflammaging.” The core prediction is that dampening mTORC1 signaling—whether through naturally occurring genetic variation or pharmacological inhibition—restores autophagic flux, reduces pro-inflammatory cytokine release, and thereby lowers systemic inflammatory burden in humans.

Evidence strength for a causal relationship remains at the scaffolding stage. By design, the swarm deprioritized non-human animal models and broad automated literature scraping in favor of human genetic instruments, human iPSC-derived cellular models, and clinical trial data. This strategy prioritizes translatability but means there are currently no completed in vitro, in vivo, or clinical findings to report. Confidence in the overall direction—that mTORC1 suppression can attenuate inflammaging via autophagy—is moderately hopeful based on existing fragmented literature, but remains low for any specific ancestry-stratified or dose-optimizable claim until the planned orthogonal streams converge. The four hypotheses updated this tick explicitly capture these uncertainties, positing testable predictions about population-specific effect modification and rapalog thresholds rather than asserting established facts.

Outstanding questions for the next tick center on three critical unknowns. First, do mTOR/autophagy-related protein quantitative trait loci truly colocalize with IL-6 and GDF-15 GWAS signals across African, East Asian, and European ancestries, or will pleiotropy and linkage disequilibrium heterogeneity undermine the genetic instruments? Second, in human macrophages, what is the therapeutic window of mTORC1 inhibition that maximizes autophagic clearance (measured by LC3-II turnover and p62 degradation) without triggering compensatory SASP-like secretion? Third, do existing sirolimus and everolimus trial cohorts exhibit longitudinal reductions in plasma IL-6, GDF-15, or hsCRP that correlate with drug exposure? The swarm will prioritize executing these analyses in the coming cycle to populate the knowledge base’s first causal relations.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

This tick, the swarm launched a deliberately constrained, three-track investigation to map the mTORC1–autophagy–IL-6/GDF-15 axis using exclusively human-provenance evidence, suspending non-human animal models to maximize translatability. Rather than a single experiment, the “intervention” here is a triangulation strategy: multi-ancestry Mendelian randomization of RPTOR and TSC2 protein quantitative trait loci against circulating IL-6 and GDF-15 genome-wide association statistics; structured manual extraction of sirolimus/everolimus pharmacokinetic and pharmacodynamic trajectories from published renal transplant and tuberous sclerosis complex trials; and a de novo cellular dose-response module using ancestry-diverse human iPSC-derived macrophages treated with rapamycin. Notably, the genetic analyses explicitly stratify East Asian and African ancestry cohorts to address longstanding European-centric biases in instrumental variable research, while the cellular module pairs direct autophagy-flux readouts with conditioned-media cytokine measurements to test causality at the human cell level.

The biological mechanism under examination ties mTORC1—a central cellular hub that senses nutrients and growth signals—to the recycling process of autophagy and to inflammatory molecules linked to aging. In broad terms, when mTORC1 is chronically active, as occurs with nutrient excess and cellular senescence, it puts the brakes on autophagy and may sustain elevated levels of IL-6 and GDF-15, two proteins that circulate in the blood and are thought to drive “inflammaging,” the low-grade chronic inflammation characteristic of older age. The working model, refined across four updated hypotheses this tick, proposes that dialing down mTORC1 signaling could restore autophagic flux and thereby dampen these inflammatory outputs. Yet it is critical to note that while the knowledge base now catalogs 122 relevant entities, it currently holds zero verified relations for this specific causal chain; these links remain biologically plausible but empirically unconfirmed.

Consequently, the evidence strength for any mTORC1-targeted intervention against inflammaging is nascent. This tick produced zero new empirical findings and zero new relations; the output consists of methodological scaffolding and sharpened hypotheses rather than data. The genetic instrumental variable track relies on publicly available summary statistics and unverified assumptions about pleiotropy across ancestries. The clinical extraction must repurpose trial data from immunosuppression and oncology indications that were not designed to assess longevity endpoints. The iPSC module, though poised to offer the first direct human cell-derived causal edge, is ultimately an in vitro system that cannot capture tissue-level or systemic feedback. The swarm has therefore deprioritized expansion into orthogonal hallmarks such as telomere attrition or epigenetic clocks until at least one of these human tracks yields a validated dose-response curve or robust genetic colocalization.

Looking ahead, the swarm must determine whether RPTOR/TSC2 variation causally modifies IL-6 and GDF-15 in an ancestry-specific manner, and whether rapamycin-induced autophagy flux in human macrophages produces a quantifiable, concentration-dependent suppression of these cytokines. Next steps focus on executing the iPSC dose-response experiments and completing the multi-ancestry colocalization analyses to populate the first validated relations in the knowledge base. Overall confidence in the strategic direction is cautiously optimistic: the triangulation design is rigorous and the mechanistic rationale is grounded in established geroscience, but the mission maintains a guarded stance until primary human data materialize. These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

Executive Summary

This tick established an analytical scaffold to test whether mTORC1–autophagy modulation causally suppresses the inflammaging biomarkers IL-6 and GDF-15 in diverse human populations. Because the knowledge base contained 122 entities but zero causal relations, the swarm focused on three converging lines of inquiry: (1) multi-ancestry proteogenetic colocalization of mTOR/autophagy protein QTLs (near TSC2, RPTOR, ULK1, and ATG5) with circulating IL-6 and GDF-15 genome-wide association signals across European, East Asian, and African cohorts; (2) de novo parameterization of rapamycin and everolimus dose-response matrices in ancestry-diverse human iPSC-derived macrophages, measuring autophagy flux markers and secreted cytokines; and (3) structured extraction protocols to link drug exposure metrics from solid-organ transplant and tuberous sclerosis trials to longitudinal IL-6 and GDF-15 trajectories. No primary causal findings were extracted this cycle, though four hypotheses were refined.

The intervention at the center of this framework is mTORC1 inhibition by rapamycin (sirolimus) and everolimus. In accessible terms, mTORC1 functions as a cellular nutrient sensor that, when chronically active, can block autophagy—the cellular recycling program that clears damaged proteins and organelles. The working hypothesis is that partial inhibition of mTORC1 restores autophagic flux, which in turn dampens the secretion of inflammatory and stress signals such as IL-6 and GDF-15. If this dose-resolvable link holds across genetic ancestries, it could anchor a pharmacological strategy to mitigate systemic inflammaging. It must be stressed, however, that this mechanism remains a directed hypothesis; the causal arrows and effect sizes in humans are exactly what the current triangulation effort seeks to establish.

Evidence strength for the mTORC1–autophagy–IL-6/GDF-15 axis in our current graph is effectively absent. This tick produced zero new findings and zero relations, with the knowledge base still populated primarily by background and review literature rather than primary causal data. No human clinical, animal, or in vitro causal edges were validated during this cycle. While the genetic instruments, cellular assays, and clinical trial extraction frames have been scoped and parameterized, they have not yet yielded quantified causal links. Therefore, any inference that rapamycin reduces inflammaging through this specific pathway remains unproven within this knowledge base.

Outstanding questions for the next tick center on execution and validation. Can multi-ancestry colocalization detect shared causal variants between mTOR/autophagy pQTLs and IL-6/GDF-15 GWAS signals, and do effect sizes differ by ancestry? Will the iPSC-macrophage experiments generate consistent EC50/Emax surfaces showing that autophagy flux predicts cytokine suppression across drug concentrations and durations? And do published transplant and TSC trials contain sufficient longitudinal biomarker density to serve as a human dose-response validation layer? The mission will continue to deprioritize unrelated aging hallmarks and non-human animal studies until at least one edge in this axis achieves human validation.

Overall confidence in the scientific direction is cautiously hopeful but necessarily tempered. The mTOR pathway is a biologically plausible geroscience target, yet the mission has not extracted a single human-provenance causal relation for this axis. The triangulation strategy is methodologically sound, but the project remains at the starting line, with the next ticks determining whether these parameterized frames yield actionable, ancestry-aware causal edges.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.

Executive Summary — Gonka Labs Longevity Research Mission

This tick, the swarm executed a tightly scoped, three-pronged investigation of the mTORC1–autophagy–inflammaging axis, asking whether suppression of mTORC1 signaling can causally reduce circulating IL-6 and GDF-15—two biomarkers of systemic stress and inflammation—by restoring macroautophagy. The workstreams ran in parallel: (1) two-sample Mendelian randomization and colocalization using protein quantitative trait loci (pQTLs) near core mTOR/autophagy genes (TSC2, RPTOR, ULK1, ATG5) against inflammatory biomarkers in European-ancestry cohorts, alongside an audit of available East Asian and African summary statistics; (2) structured extraction of pharmacokinetic and pharmacodynamic trajectories from human sirolimus and everolimus trials in kidney/liver transplant and tuberous sclerosis complex (TSC) patients; and (3) experimental design for an ancestry-diverse iPSC-derived macrophage study to test low-dose rapamycin and everolimus effects on autophagy flux and secreted cytokines. No new causal findings were produced this cycle; the knowledge base expanded by 122 entities and five hypotheses were refined, but the relation count remains at zero, reflecting that this phase was foundational—focused on instrument calibration, literature scaffolding, and hypothesis sharpening rather than empirical discovery.

The central biological hypothesis is that clinically relevant mTORC1 inhibition acts as a “cellular recycling switch.” In everyday terms, mTORC1 is a nutrient sensor that, when chronically overactive with age, suppresses autophagy—the process by which cells degrade damaged proteins and organelles. This accumulated cellular “clutter” is thought to drive a low-grade inflammatory state dubbed “inflammaging,” reflected in elevated IL-6 and GDF-15. The most interesting intervention under evaluation is therefore not a novel molecule, but the precise calibration of low-dose rapalog exposure (0.1–2 nM) to determine whether it can restore autophagic flux in human macrophages and, as a downstream consequence, lower secretion of these inflammaging mediators. The swarm is specifically seeking a human-provenance causal edge: genetic instrumental variables from human populations, biomarker trajectories from human transplant cohorts, and mechanistic validation in human iPSC-derived cells.

At present, the evidence strength for this specific causal chain is unestablished. The planned evidentiary hierarchy is deliberately human-centric: genetic association data (currently weighted toward European ancestries, with recognized multi-ancestry gaps), aggregated clinical biomarker data from human transplant and TSC trials, and forthcoming in vitro data from human macrophages. Non-human animal models were intentionally deprioritized this cycle to prioritize translational relevance, though this choice sacrifices some mechanistic depth that preclinical in vivo work could provide. Key limitations include the uncertain availability of sufficiently powered pQTL instruments, sparse reporting of IL-6 and GDF-15 at sub-immunosuppressive rapalog doses in the transplant literature, and the inherent constraints of iPSC models in capturing in vivo tissue microenvironments.

Outstanding questions for the next tick center on three unknowns. First, are the selected pQTL instruments strong and specific enough to detect a causal effect of mTOR/autophagy pathway variation on systemic inflammation, and can those signals be validated—or even detected—across East Asian and African genetic backgrounds? Second, can the structured clinical extraction yield a coherent human dose-response scaffold linking drug exposure (C0 trough or AUC-normalized brackets) to pS6 suppression and downstream IL-6/GDF-15 dynamics? Third, in the iPSC macrophage atlas, does low-dose rapamycin or everolimus produce measurable autophagy flux—quantified via LC3-II/p62 turnover with bafilomycin A1 clamp—within 6–24 hours, and does that flux correlate with reduced cytokine secretion before any supratherapeutic testing is justified?

Overall confidence in the strategic direction is cautiously optimistic but rigorously bounded. The triangulation of genetic epidemiology, clinical pharmacology, and human cellular mechanistics represents a coherent, high-conviction path to a human-relevant proof-of-concept. However, the honest assessment is that this remains an unvalidated causal model. The decision to narrow the aperture exclusively to the mTORC1–autophagy–IL-6/GDF-15 axis—and to set aside parallel longevity pathways such as sirtuin activation or epigenetic reprogramming—reflects a deliberate bet that still awaits its first positive empirical result. The next tick will focus on closing the multi-ancestry data gap, initiating the iPSC macrophage experiments, and stress-testing whether extracted clinical PK/PD trajectories can support a viable human dose-response hypothesis.

These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.